Blanche C Ip1, Chun Liu2, Alice H Lichtenstein3, Johannes von Lintig4, Xiang-Dong Wang5. 1. Nutrition and Cancer Biology Laboratory, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA; and. 2. Nutrition and Cancer Biology Laboratory. 3. Cardiovascular Nutrition Laboratory, Jean-Mayer USDA Human Nutrition Research Center on Aging, and Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA; and. 4. Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH. 5. Nutrition and Cancer Biology Laboratory, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA; and xiang-dong.wang@tufts.edu.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease is positively associated with obesity and cardiovascular disease risk. Apo-10'-lycopenoic acid (APO10LA), a potential oxidation product of apo-10'-lycopenal that is generated endogenously by β-carotene-9',10'-oxygenase (BCO2) cleavage of lycopene, inhibited hepatic steatosis in BCO2-expressing mice. OBJECTIVE: The present study evaluated lycopene and APO10LA effects on hepatic steatosis in mice without BCO2 expression. METHODS: Male and female BCO2-knockout (BCO2-KO) mice were fed a high saturated fat diet (HSFD) with or without APO10LA (10 mg/kg diet) or lycopene (100 mg/kg diet) for 12 wk. RESULTS: Lycopene or APO10LA supplementation reduced hepatic steatosis incidence (78% and 72%, respectively) and severity in BCO2-KO male mice. Female mice did not develop steatosis, had greater hepatic total cholesterol (3.06 vs. 2.31 mg/g tissue) and cholesteryl ester (1.58 vs. 0.86 mg/g tissue), but had lower plasma triglyceride (TG) (229 vs. 282 mg/dL) and cholesterol (97.1 vs. 119 mg/dL) than male mice. APO10LA-mitigated steatosis in males was associated with reduced hepatic total cholesterol (18%) and activated sirtuin 1 signaling, which resulted in reduced fatty acids (FAs) and TG synthesis markers [stearoyl-coenzyme A (CoA) desaturase protein, 71%; acetyl-CoA carboxylase phosphorylation, 79%; AMP-activated protein kinase phosphorylation, 67%], and elevated cholesterol efflux genes (cytochrome P450 family 7A1, 65%; ATP-binding cassette transporter G5/8, 11%). These APO10LA-mediated effects were not mimicked by lycopene supplementation. Intriguingly, steatosis inhibition by lycopene induced peroxisome proliferator-activated receptor (PPAR)α- and PPARγ-related genes in mesenteric adipose tissue (MAT) that increases mitochondrial uncoupling [cell death-inducing DNA fragmentation factor, α subunit-like effector a, 55%; PR domain-containing 16, 47%; uncoupling protein 3 (Ucp3), 55%], FA β-oxidation (PPARα, 53%; very long chain acyl-CoA dehydrogenase, 38%), and uptake (FA transport protein 4, 29%; lipoprotein lipase 43%). Expressions of 10 MAT PPAR-related genes were inversely correlated with steatosis score, suggesting that lycopene reduced steatosis by increasing MAT FA utilization. CONCLUSIONS: Our data suggest that lycopene and APO10LA inhibit HSFD-induced steatosis in BCO2-KO male mice through differential mechanisms. Sex disparity of BCO2-KO mice was observed in the outcomes of HSFD-induced liver steatosis and plasma lipids.
BACKGROUND:Nonalcoholic fatty liver disease is positively associated with obesity and cardiovascular disease risk. Apo-10'-lycopenoic acid (APO10LA), a potential oxidation product of apo-10'-lycopenal that is generated endogenously by β-carotene-9',10'-oxygenase (BCO2) cleavage of lycopene, inhibited hepatic steatosis in BCO2-expressing mice. OBJECTIVE: The present study evaluated lycopene and APO10LA effects on hepatic steatosis in mice without BCO2 expression. METHODS: Male and female BCO2-knockout (BCO2-KO) mice were fed a high saturated fat diet (HSFD) with or without APO10LA (10 mg/kg diet) or lycopene (100 mg/kg diet) for 12 wk. RESULTS:Lycopene or APO10LA supplementation reduced hepatic steatosis incidence (78% and 72%, respectively) and severity in BCO2-KO male mice. Female mice did not develop steatosis, had greater hepatic total cholesterol (3.06 vs. 2.31 mg/g tissue) and cholesteryl ester (1.58 vs. 0.86 mg/g tissue), but had lower plasma triglyceride (TG) (229 vs. 282 mg/dL) and cholesterol (97.1 vs. 119 mg/dL) than male mice. APO10LA-mitigated steatosis in males was associated with reduced hepatic total cholesterol (18%) and activated sirtuin 1 signaling, which resulted in reduced fatty acids (FAs) and TG synthesis markers [stearoyl-coenzyme A (CoA) desaturase protein, 71%; acetyl-CoA carboxylase phosphorylation, 79%; AMP-activated protein kinase phosphorylation, 67%], and elevated cholesterol efflux genes (cytochrome P450 family 7A1, 65%; ATP-binding cassette transporter G5/8, 11%). These APO10LA-mediated effects were not mimicked by lycopene supplementation. Intriguingly, steatosis inhibition by lycopene induced peroxisome proliferator-activated receptor (PPAR)α- and PPARγ-related genes in mesenteric adipose tissue (MAT) that increases mitochondrial uncoupling [cell death-inducing DNA fragmentation factor, α subunit-like effector a, 55%; PR domain-containing 16, 47%; uncoupling protein 3 (Ucp3), 55%], FA β-oxidation (PPARα, 53%; very long chain acyl-CoA dehydrogenase, 38%), and uptake (FA transport protein 4, 29%; lipoprotein lipase 43%). Expressions of 10 MAT PPAR-related genes were inversely correlated with steatosis score, suggesting that lycopene reduced steatosis by increasing MAT FA utilization. CONCLUSIONS: Our data suggest that lycopene and APO10LA inhibit HSFD-induced steatosis in BCO2-KO male mice through differential mechanisms. Sex disparity of BCO2-KO mice was observed in the outcomes of HSFD-induced liver steatosis and plasma lipids.
Authors: Anna Kotronen; Hannele Yki-Järvinen; Ksenia Sevastianova; Robert Bergholm; Antti Hakkarainen; Kirsi H Pietiläinen; Leena Juurinen; Nina Lundbom; Thorkild I A Sørensen Journal: Obesity (Silver Spring) Date: 2010-06-10 Impact factor: 5.002
Authors: Andrew Paul DeFilippis; Michael J Blaha; Seth S Martin; Robert M Reed; Steven R Jones; Khurram Nasir; Roger S Blumenthal; Matthew J Budoff Journal: Atherosclerosis Date: 2013-01-29 Impact factor: 5.162
Authors: Maryam Ahmadian; Jae Myoung Suh; Nasun Hah; Christopher Liddle; Annette R Atkins; Michael Downes; Ronald M Evans Journal: Nat Med Date: 2013-05-07 Impact factor: 53.440
Authors: Lin Zhu; William C Brown; Qing Cai; Andrée Krust; Pierre Chambon; Owen P McGuinness; John M Stafford Journal: Diabetes Date: 2012-09-10 Impact factor: 9.461
Authors: Lei Wu; Xin Guo; Weiqun Wang; Denis M Medeiros; Stephen L Clarke; Edralin A Lucas; Brenda J Smith; Dingbo Lin Journal: Exp Biol Med (Maywood) Date: 2016-07-07
Authors: Jelena Mustra Rakic; Chun Liu; Sudipta Veeramachaneni; Dayong Wu; Ligi Paul; C-Y Oliver Chen; Lynne M Ausman; Xiang-Dong Wang Journal: Cancer Prev Res (Phila) Date: 2019-06-08
Authors: Hsueh-Li Tan; Jennifer M Thomas-Ahner; Nancy E Moran; Jessica L Cooperstone; John W Erdman; Gregory S Young; Steven K Clinton Journal: Cancer Prev Res (Phila) Date: 2016-11-02
Authors: Koichi Aizawa; Chun Liu; Sanyuan Tang; Sudipta Veeramachaneni; Kang-Quan Hu; Donald E Smith; Xiang-Dong Wang Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: Nancy E Moran; Jennifer M Thomas-Ahner; Lei Wan; Krystle E Zuniga; John W Erdman; Steven K Clinton Journal: J Nutr Date: 2022-06-09 Impact factor: 4.687